1.
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
by Van Assche, Gert
Gut, 2012, Vol.61 (2), p.229-234
2.
3.
Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis
by Hendy, P.
Alimentary pharmacology & therapeutics, 2015, Vol.41 (1), p.149-149
4.
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with...
by Park, Won
Annals of the rheumatic diseases, 2013, Vol.72 (10), p.1605-1612
5.
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
by Ungar, Bella
Gut, 2014, Vol.63 (8), p.1258-1264
6.
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexat...
by Yoo, Dae Hyun
Annals of the rheumatic diseases, 2013, Vol.72 (10), p.1613-1620
7.
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis des...
by Smolen, Josef S
Annals of the rheumatic diseases, 2014, Vol.73 (9), p.1616-1625
8.
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
by Bartelds, Geertje M
Annals of the rheumatic diseases, 2007, Vol.66 (7), p.921-926
9.
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
by Sandborn, W J
Gut, 2007, Vol.56 (9), p.1232-1239
10.
11.
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
by Seow, C H
Gut, 2010, Vol.59 (1), p.49-54
12.
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
by Rutgeerts, Paul J
Gut, 2013, Vol.62 (8), p.1122-1130
13.
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
by Radstake, T R D J
Annals of the rheumatic diseases, 2009, Vol.68 (11), p.1739-1745
14.
15.
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
by Leav, Brett A
Vaccine, 2009, Vol.28 (4), p.965-969
16.
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease
by Vermeire, Severine
Gut, 2007, Vol.56 (9), p.1226-1231
17.
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
by Vande Casteele, N.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (8), p.765-771
18.
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
by Vande Casteele, Niels
Gut, 2015, Vol.64 (10), p.1539-1545
19.
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids
by Noonan, Michael, MD
Journal of allergy and clinical immunology, 2013, Vol.132 (3), p.567-574.e12
20.
